Health Economics›Breast cancer›Adjuvant therapy

Adjuvant therapy

Breast cancer · 74 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 10 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
TCHP (Docetaxel) Variant #01	ERBB2	R 77 812	21d	—	—	—	—	1
Olaparib monotherapy Variant #01	BRCA	R 59 224	28d	—	—	—	—	1
Trastuzumab emtansine monotherapy Variant #01	ERBB2	R 41 405	21d	—	—	—	—	1
Lapatinib and Trastuzumab Variant #02	ERBB2	R 38 538	28d	~2.6 mo	~14.0 mo	~3	~R 115 613 PFS proxy · indirect	2
Pertuzumab and Trastuzumab hyaluronidase monotherapy Variant #01	ERBB2	R 26 380	21d	—	—	—	—	—
Letrozole and Ribociclib Variant #01	ER	R 21 181	28d	~25.3 mo	~63.9 mo	~28	~R 593 065 PFS proxy · indirect	2
TCH (Docetaxel) Variant #01	ERBB2	R 18 211	21d	—	—	—	—	2
TCyH (Docetaxel) Variant #01	ERBB2	R 17 123	21d	—	—	—	—	—
Paclitaxel and Trastuzumab (TH) Variant #01	ERBB2	R 16 575	21d	~12.9 mo	~24.0 mo	~19	~R 314 933 PFS proxy · indirect	10
Abemaciclib and ET Variant #01	ER	R 15 920	28d	—	—	—	—	—
Anastrozole and Ribociclib Variant #01	ER	R 14 032	28d	—	—	—	—	—
Docetaxel and Trastuzumab (TH) Variant #01	ERBB2	R 12 507	21d	~12.4 mo	~26.5 mo	~18	~R 225 125 PFS proxy · indirect	11
CMF and H Variant #01	ERBB2	R 10 828	21d	—	—	—	—	—
Trastuzumab monotherapy Variant #04	ERBB2	R 10 438	21d	—	—	—	—	2
FEC and H Variant #01	ERBB2	R 6 657	21d	—	—	—	—	—
CTCb Variant #01 Partial	—	R 6 280	—	—	—	—	—	1
ddEC-ECT Variant #01 Partial	—	R 4 774	21d	—	—	—	—	—
FNC Variant #01	—	R 4 371	21d	—	—	—	—	—
Exemestane monotherapy Variant #01	ER	R 2 846	90d	~3.8 mo	~45.1 mo	~2	~R 5 693 PFS proxy · indirect	10
FEC Variant #01	ERBB2	R 2 364	21d	—	—	—	—	7
Paclitaxel monotherapy Variant #46	—	R 2 220	28d	~6.4 mo	~16.8 mo	~7	~R 15 537 PFS proxy · indirect	28
CEF/CMF Variant #01	—	R 1 758	21d	—	—	—	—	—
Tamoxifen-Exemestane Variant #01	ER	R 1 022	28d	—	—	—	—	1
AVCF Variant #01	—	R 932	30d	—	—	—	—	—
PAF Variant #01	—	R 829	42d	—	—	—	—	—
CPB Variant #01 Partial	—	R 793	—	—	—	—	—	—
FAC and BCG Variant #01	—	R 780	28d	—	—	—	—	—
Cyclophosphamide and Doxorubicin (AC) Variant #01	—	R 718	21d	—	—	—	—	1
Fluorouracil and Methotrexate (MF) Variant #03	—	R 682	14d	—	—	—	—	—
CAMFP Variant #01	—	R 646	21d	—	—	—	—	—
CMFPT Variant #01	—	R 646	28d	—	—	—	—	—
ACT Variant #01	ER	R 639	28d	—	—	—	—	2
ACT Variant #01	—	R 639	28d	—	—	—	—	2
CMFT Variant #01	ER	R 585	28d	—	—	—	—	—
CMFP Variant #01	—	R 509	28d	—	—	—	—	—
Letrozole-Tamoxifen Variant #01	ER	R 508	28d	—	—	—	—	—
Tamoxifen-Letrozole Variant #01	ER	R 508	28d	—	—	—	—	—
Toremifene monotherapy Variant #01	ER	R 494	28d	—	—	—	—	—
PFT Variant #01	ER	R 459	42d	—	—	—	—	—
PFT Variant #01	—	R 459	42d	—	—	—	—	—
CFP Variant #01	—	R 431	42d	—	—	—	—	—
Tamoxifen monotherapy Variant #06	ER	R 410	28d	—	—	—	—	3
CFP and Bilateral oophorectomy Variant #01	ER	R 393	35d	—	—	—	—	—
Letrozole monotherapy Variant #01	ER	R 371	28d	~14.5 mo	~51.3 mo	~16	~R 5 934 PFS proxy · indirect	16
Tamoxifen-Anastrozole Variant #01	ER	R 296	28d	—	—	—	—	1
CMFVP Variant #01	—	R 256	7d	—	—	—	—	—
PF Variant #01	—	R 254	42d	—	—	—	—	—
Anastrozole monotherapy Variant #01	ER\|ERBB2	R 159	28d	~13.8 mo	~42.7 mo	~16	~R 2 546 PFS proxy · indirect	12
Anastrozole monotherapy Variant #01	ER	R 159	28d	~13.8 mo	~42.7 mo	~16	~R 2 546 PFS proxy · indirect	12
PT Variant #01	—	R 145	28d	—	—	—	—	—
PT Variant #01	ER	R 145	28d	—	—	—	—	—
TMF Variant #01 Partial	—	R 140	42d	—	—	—	—	—
Melphalan monotherapy Variant #01	—	R 71	42d	~50.0 mo	~22.2 mo	~37	~R 2 636 PFS proxy · indirect	7
Neratinib monotherapy N/A - secondary systemic drug	ERBB2	R 62	28d	—	—	—	—	1
Cyclophosphamide monotherapy N/A - secondary systemic drug	—	R 60	28d	—	~15.8 mo	—	—	1
Placebo Partial	TNBC	—	—	—	—	—	—	1
Thiotepa monotherapy Variant #01 Partial	—	—	3d	—	—	—	—	—
Bilateral oophorectomy Partial	ER	—	—	—	—	—	—	—
AVCMF Partial	—	—	—	—	—	—	—	—
Placebo Partial	—	—	—	—	—	—	—	1
Bilateral Oophorectomy Partial	ER	—	—	—	—	—	—	—
Placebo Partial	ER	—	—	—	—	—	—	1
Oophorectomy Partial	—	—	—	—	—	—	—	—
Levamisole monotherapy Variant #01 Partial	—	—	14d	—	—	—	—	—
Trastuzumab and hyaluronidase monotherapy Variant #01 Partial	ERBB2	—	21d	—	—	—	—	—
CFP and Oophorectomy Partial	—	—	—	—	—	—	—	—
CMFL Partial	—	—	—	—	—	—	—	—
Observation Partial	ER	—	—	—	—	—	—	1
Observation Partial	—	—	—	—	—	—	—	1
Observation Partial	TNBC	—	—	—	—	—	—	1
Aromatase inhibitor monotherapy Variant #01 Partial	ER	—	—	—	—	—	—	—
Observation Partial	ERBB2	—	—	—	—	—	—	1
Placebo Partial	ERBB2	—	—	—	—	—	—	1
Radiation therapy N/A - radiation Partial	—	—	49d	~25.5 mo	~10.6 mo	~16	—	24

74 of 74 regimens shown